NEWS
Find a Professional: Explore Experts Across 197 Disciplines in 221 Countries!
Just Updated: Compare Your Institution (Live Data)
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025 (Updated Today)
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
Login
Register & Pricing
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
For Students
local_fire_department
Country Reports
person
Find a Professional
Ryan N Ptashkin
University of Michigan - Ann Arbor / United States
Engineering & Technology / Computer Science
AD Scientific Index ID: 1293288
Registration, Add Profile,
Premium Membership
Get Your Global Impact Certificate
University of Michigan
Ranking &
Analysis
Job
Experiences
Education
Information
Published Books
Book Chapters
Articles
Presentations
Lessons
Projects
Co-Authors
Subject Leaders
Editorship, Referee &
Scientific Board
Patents /
Designs
Academic Grants
& Awards
Artistic
Activities
Certificate / Course
/ Trainings
Association &
Society Memberships
Contact, Office
& Social Media
person_outline
Ryan N Ptashkin's MOST POPULAR ARTICLES
1-)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients Nature medicine 23 (6), 703-713, 2017
2-)
Cancer therapy shapes the fitness landscape of clonal hematopoiesis Nature genetics 52 (11), 1219-1226, 2020
3-)
Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention Clinical Cancer Research 24 (17), 4154-4161, 2018
4-)
High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden Clinical Cancer Research 25 (15), 4712-4722, 2019
5-)
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial The Lancet Oncology 21 (6), 821-831, 2020
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept